<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cutaneous T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> other than <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e>, <z:e sem="disease" ids="C0036920" disease_type="Neoplastic Process" abbrv="">Sezary syndrome</z:e>, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of <z:hpo ids='HP_0000001'>all</z:hpo> cutaneous T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Primary cutaneous small/medium CD4+ T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a member of this third group of cutaneous <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> (WHO-EORTC) classification </plain></SENT>
<SENT sid="2" pm="."><plain>It still awaits development of more precise diagnostic criteria and optimal therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accompanied with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> successfully treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>It seems that <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option </plain></SENT>
</text></document>